Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
154 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cough - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Cough - Pipeline Review, H1 2015', provides an overview of the Cough's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cough - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cough and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cough pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cough - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cough Overview 9 Therapeutics Development 10 Pipeline Products for Cough - Overview 10 Pipeline Products for Cough - Comparative Analysis 11 Cough - Therapeutics under Development by Companies 12 Cough - Therapeutics under Investigation by Universities/Institutes 16 Cough - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Cough - Products under Development by Companies 21 Cough - Products under Investigation by Universities/Institutes 24 Cough - Companies Involved in Therapeutics Development 25 Afferent Pharmaceuticals, Inc. 25 Ahn-Gook Pharmaceutical Co., Ltd. 26 Alitair Pharmaceuticals, Inc. 27 Ario Pharma Ltd 28 AUS Bio Limited 29 Beijing Minhai Biotechnology Co., Ltd 30 Beijing Tiantan Biological Products Co., Ltd. 31 Bharat Biotech International Limited 32 Biological E. Limited 33 Daewoong Pharmaceutical Co., Ltd. 34 Daiichi Sankyo Company, Limited 35 DBV Technologies S.A. 36 GlaxoSmithKline plc 37 Glenmark Pharmaceuticals Ltd. 38 Green Cross Corporation 39 Hanmi Pharmaceuticals, Co. Ltd. 40 Hydra Biosciences, Inc. 41 Hyundai Pharmaceutical Co., Ltd. 42 Indian Immunologicals Limited 43 LG Life Sciences, Ltd. 44 NanoBio Corporation 45 Neos Therapeutics, Inc. 46 Novartis AG 47 Orbis Biosciences, Inc. 48 Panacea Biotec Limited 49 Sanofi 50 Sanofi Pasteur SA 51 Serum Institute of India Limited 52 Sinovac Biotech Ltd. 53 Synthetic Biologics, Inc. 54 Tesaro, Inc. 55 Vectura Group plc 56 Vernalis plc 57 Zydus Cadila Healthcare Limited 58 Cough - Therapeutics Assessment 59 Assessment by Monotherapy Products 59 Assessment by Combination Products 60 Assessment by Target 61 Assessment by Mechanism of Action 63 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 (ambroxol + levodropropizine) - Drug Profile 69 (chlorpheniramine maleate + codeine) - Drug Profile 70 (diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine - Drug Profile 71 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine - Drug Profile 72 AF-219 - Drug Profile 74 AG-1321001 - Drug Profile 76 AG-1321001-SY - Drug Profile 77 AGPPC-709 - Drug Profile 78 benzonatate polacrilex - Drug Profile 79 CCP-01 - Drug Profile 80 CCP-05 - Drug Profile 81 CCP-06 - Drug Profile 82 CCP-07 - Drug Profile 83 CCP-08 - Drug Profile 84 diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine - Drug Profile 85 diphtheria + pertussis + tetanus vaccine - Drug Profile 86 diphtheria + pertussis + tetanus vaccine - Drug Profile 87 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 88 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 89 diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine - Drug Profile 90 diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine - Drug Profile 91 diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile 92 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile 93 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 94 diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile 95 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 96 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 97 diphtheria + tetanus+ pertussis vaccine - Drug Profile 98 diptheria + tetanus + pertussis (whole-cell) vaccine - Drug Profile 99 DTaP Vaccine - Drug Profile 100 DWJ-1340 - Drug Profile 101 GC-3111A - Drug Profile 102 GRC-17536 - Drug Profile 103 GSK-2339345 - Drug Profile 104 guaifenesin ER - Drug Profile 105 HC-030031 - Drug Profile 107 HOB-048 - Drug Profile 109 LPCN-1087 - Drug Profile 110 LPCN-1090 - Drug Profile 111 MD-990 - Drug Profile 112 pertussis (acellular) vaccine - Drug Profile 113 pertussis (acellular) vaccine - Drug Profile 114 pertussis (whole-cell) vaccine - Drug Profile 115 pertussis + hepatitis B vaccine - Drug Profile 116 pertussis vaccine - Drug Profile 117 pertussis vaccine - Drug Profile 118 pertussis vaccine - Drug Profile 119 pertussis vaccine - Drug Profile 120 pertussis vaccine - Drug Profile 121 Recombinant BCG - Pertussis Vaccine - Drug Profile 122 SCH-900978 - Drug Profile 123 Small Molecule for Cough and Cold - Drug Profile 124 Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile 125 SYN-005 - Drug Profile 126 tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile 127 VN-0103 - Drug Profile 128 VR-611 - Drug Profile 129 XEND-0501 - Drug Profile 130 Cough - Recent Pipeline Updates 132 Cough - Dormant Projects 138 Cough - Discontinued Products 142 Cough - Product Development Milestones 143 Featured News & Press Releases 143 Appendix 149 Methodology 149 Coverage 149 Secondary Research 149 Primary Research 149 Expert Panel Validation 149 Contact Us 149 Disclaimer 150
List of Tables Number of Products under Development for Cough, H1 2015 14 Number of Products under Development for Cough - Comparative Analysis, H1 2015 15 Number of Products under Development by Companies, H1 2015 17 Number of Products under Development by Companies, H1 2015 (Contd..1) 18 Number of Products under Development by Companies, H1 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2015 20 Comparative Analysis by Late Stage Development, H1 2015 21 Comparative Analysis by Clinical Stage Development, H1 2015 22 Comparative Analysis by Early Stage Development, H1 2015 23 Comparative Analysis by Unknown Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Investigation by Universities/Institutes, H1 2015 28 Cough - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 29 Cough - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 30 Cough - Pipeline by Alitair Pharmaceuticals, Inc., H1 2015 31 Cough - Pipeline by Ario Pharma Ltd, H1 2015 32 Cough - Pipeline by AUS Bio Limited, H1 2015 33 Cough - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 34 Cough - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 35 Cough - Pipeline by Bharat Biotech International Limited, H1 2015 36 Cough - Pipeline by Biological E. Limited, H1 2015 37 Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 38 Cough - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 39 Cough - Pipeline by DBV Technologies S.A., H1 2015 40 Cough - Pipeline by GlaxoSmithKline plc, H1 2015 41 Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 42 Cough - Pipeline by Green Cross Corporation, H1 2015 43 Cough - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 44 Cough - Pipeline by Hydra Biosciences, Inc., H1 2015 45 Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 46 Cough - Pipeline by Indian Immunologicals Limited, H1 2015 47 Cough - Pipeline by LG Life Sciences, Ltd., H1 2015 48 Cough - Pipeline by NanoBio Corporation, H1 2015 49 Cough - Pipeline by Neos Therapeutics, Inc., H1 2015 50 Cough - Pipeline by Novartis AG, H1 2015 51 Cough - Pipeline by Orbis Biosciences, Inc., H1 2015 52 Cough - Pipeline by Panacea Biotec Limited, H1 2015 53 Cough - Pipeline by Sanofi, H1 2015 54 Cough - Pipeline by Sanofi Pasteur SA, H1 2015 55 Cough - Pipeline by Serum Institute of India Limited, H1 2015 56 Cough - Pipeline by Sinovac Biotech Ltd., H1 2015 57 Cough - Pipeline by Synthetic Biologics, Inc., H1 2015 58 Cough - Pipeline by Tesaro, Inc., H1 2015 59 Cough - Pipeline by Vectura Group plc, H1 2015 60 Cough - Pipeline by Vernalis plc, H1 2015 61 Cough - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 62 Assessment by Monotherapy Products, H1 2015 63 Assessment by Combination Products, H1 2015 64 Number of Products by Stage and Target, H1 2015 66 Number of Products by Stage and Mechanism of Action, H1 2015 68 Number of Products by Stage and Route of Administration, H1 2015 70 Number of Products by Stage and Molecule Type, H1 2015 72 Cough Therapeutics - Recent Pipeline Updates, H1 2015 136 Cough - Dormant Projects, H1 2015 142 Cough - Dormant Projects (Contd..1), H1 2015 143 Cough - Dormant Projects (Contd..2), H1 2015 144 Cough - Dormant Projects (Contd..3), H1 2015 145 Cough - Discontinued Products, H1 2015 146
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
